INVO Fertility (IVF) AI Stock Analysis

• Market Cap: $2.78M
• Dividend Yield: N/A
• Average Volume (3M): 8.28M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.29
• Revenue Growth: 11.50%
• EPS Growth: 2.37%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -6.16
• Shares Outstanding: 5,624,012
• 10 Day Avg. Volume: 24,408,967
• 30 Day Avg. Volume: 8,279,900
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.24
• Price to Sales (P/S): 0.46
• P/FCF Ratio: -0.95
• Enterprise Value/Market Cap: 6.39
• Enterprise Value/Revenue: 2.56
• Enterprise Value/Gross Profit: 6.52
• Enterprise Value/Ebitda: -0.73
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: $1.50 ▼(-2.60% Downside)

INVO Fertility faces significant financial challenges, with negative profitability and cash flow issues being the most critical factors. Technical analysis indicates bearish momentum, and the valuation is unattractive due to the negative P/E ratio. These factors collectively result in a low overall stock score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a strong demand for IVF services, suggesting a solid market position and potential for future profitability.

Leverage Management

Improved leverage management enhances financial stability, providing the company with greater flexibility to invest in growth opportunities.

Strategic Partnerships

Strategic partnerships can enhance revenue streams and provide access to new technologies, strengthening the company's competitive position.

Negative Factors

Profitability Challenges

Ongoing profitability challenges may limit the company's ability to reinvest in growth and could impact long-term financial health.

Cash Flow Issues

Negative cash flows indicate operational inefficiencies, which could hinder the company's ability to fund operations and growth initiatives.

Decreasing Gross Profit Margin

A declining gross profit margin suggests increased cost pressures, which could erode profitability and affect long-term competitiveness.

INVO Fertility Business Overview & Revenue Model

Company Description

INVO Fertility, Inc. operates as a revenue-generating fertility business. It also focuses on the development of class clinical-stage assets in oncology and autoimmune diseases. The company was founded on January 5, 2007 and is headquartered in Sarasota, FL.

How the Company Makes Money

INVO Fertility generates revenue primarily through the provision of IVF services and related fertility treatments. The company charges patients for various services including initial consultations, diagnostic tests, IVF cycles, egg retrievals, and embryo transfers. Additional revenue streams include payments for ancillary services such as sperm banking, genetic testing, and medication prescriptions. INVO Fertility may also partner with insurance companies to offer patients coverage options, which can further enhance revenue. Additionally, the company may engage in strategic partnerships with pharmaceutical companies for the supply of fertility medications, which can provide additional income through negotiated agreements.

INVO Fertility Financial Statement Overview

Summary

INVO Fertility is experiencing revenue growth, but significant challenges remain in achieving profitability and efficient cash flow management. The company has improved its leverage position, but negative returns on equity and persistent losses indicate underlying operational inefficiencies. Continued focus on cost management and operational improvements is necessary to enhance financial health.

Income Statement

INVO Fertility's income statement shows a consistent increase in revenue over the years, with a TTM revenue growth rate of 4.89%. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin has decreased from 96.51% in 2021 to 39.17% in TTM, reflecting increased cost pressures. Overall, the company is experiencing growth but is facing significant profitability challenges.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 0.72 in TTM, which is an improvement from previous years, indicating better leverage management. However, the return on equity remains negative, suggesting inefficiencies in generating returns on shareholder investments. The equity ratio is not explicitly calculated, but the company's equity position has been volatile, impacting financial stability.

Cash Flow

INVO Fertility's cash flow statement highlights challenges in cash generation, with negative operating and free cash flows. The free cash flow growth rate is positive at 17.27% in TTM, indicating some improvement. However, the operating cash flow to net income ratio is negative, reflecting ongoing operational inefficiencies. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is somewhat aligned with net income, despite being negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.94M	6.53M	3.02M	822.20K	4.16M	1.04M
Gross Profit	2.72M	2.87M	1.09M	-28.57K	4.02M	948.53K
EBITDA	-24.39M	-7.14M	-6.88M	-10.75M	-5.22M	-5.48M
Net Income	-28.96M	-9.10M	-8.03M	-10.89M	-6.65M	-8.35M
Balance Sheet
Total Assets	18.83M	46.45M	18.51M	3.71M	10.47M	10.95M
Cash, Cash Equivalents and Short-Term Investments	355.89K	741.40K	232.42K	90.14K	5.68M	10.10M
Total Debt	4.23M	9.90M	6.30M	2.27M	2.12M	775.02K
Total Liabilities	12.98M	33.70M	17.61M	4.69M	3.16M	5.20M
Stockholders Equity	5.85M	12.75M	892.83K	-977.61K	7.31M	5.74M
Cash Flow
Free Cash Flow	-7.77M	-3.16M	-5.20M	-6.62M	-6.48M	-4.86M
Operating Cash Flow	-7.66M	-2.97M	-4.76M	-6.60M	-6.03M	-4.78M
Investing Cash Flow	354.98K	363.89K	-2.49M	-81.22K	-2.15M	-187.25K
Financing Cash Flow	7.19M	3.12M	7.39M	1.09M	3.77M	13.82M

INVO Fertility Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVF, the sentiment is Negative. The current price of 1.54 is below the 20-day moving average (MA) of 2.87, below the 50-day MA of 4.48, and below the 200-day MA of 28.85, indicating a bearish trend. The MACD of -0.90 indicates Positive momentum. The RSI at 30.04 is Neutral, neither overbought nor oversold. The STOCH value of 17.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVF.

INVO Fertility Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IVF	39 Underperform	$2.78M	>-0.01	-922.88%	―	11.50%	2.37%

INVO Fertility Corporate Events

INVO Fertility Investor Exercises Additional Investment Right

On October 16, 2025, an institutional investor of INVO Fertility exercised its Additional Investment Right to acquire 500 shares of Series C-2 Convertible Preferred Stock for $500,000. This transaction adjusted the conversion price to $0.6285 per share and was conducted without registration under the Securities Act, impacting the company’s financial structure and shareholder composition.

The most recent analyst rating on (IVF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.

INVO Fertility Announces New Preferred Stock Investment

On October 6, 2025, an institutional investor in INVO Fertility, Inc. exercised its Additional Investment Right to acquire 200 shares of Series C-2 Convertible Preferred Stock for $200,000. This transaction resulted in an adjusted conversion price of $0.6643 per share and was conducted as a private offering under the Securities Act exemptions, impacting the company’s financial structure and shareholder equity.

The most recent analyst rating on (IVF) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.

INVO Fertility Sees Institutional Investor Stock Acquisition

On September 8, 2025, INVO Fertility, Inc. saw an institutional investor exercise its Additional Investment Right to acquire 200 shares of Series C-2 Convertible Preferred Stock for $200,000. This transaction adjusted the conversion price to $0.7362 per share and was executed without registration under the Securities Act, relying on exemptions for non-public offerings.

The most recent analyst rating on (IVF) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.

INVO Fertility Amends Financial Agreement with Five Narrow Lane

On August 21, 2025, INVO Fertility, Inc. and Five Narrow Lane LP amended their financial agreement, reducing the principal amount of a debenture and exchanging it for preferred stock shares. Additionally, they extended deadlines for filing and effectiveness of a registration statement with the SEC, impacting the company’s financial operations and stakeholder interests.

The most recent analyst rating on (IVF) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.